[go: up one dir, main page]

WO1997005267A3 - Mucosal delivery of polynucleotides - Google Patents

Mucosal delivery of polynucleotides Download PDF

Info

Publication number
WO1997005267A3
WO1997005267A3 PCT/US1996/012041 US9612041W WO9705267A3 WO 1997005267 A3 WO1997005267 A3 WO 1997005267A3 US 9612041 W US9612041 W US 9612041W WO 9705267 A3 WO9705267 A3 WO 9705267A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
animal
binding protein
polynucleotides
mucosal delivery
Prior art date
Application number
PCT/US1996/012041
Other languages
French (fr)
Other versions
WO1997005267A2 (en
Inventor
Dannie H King
Original Assignee
Maxim Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharmaceuticals filed Critical Maxim Pharmaceuticals
Priority to JP9507664A priority Critical patent/JPH11510164A/en
Priority to AU65057/96A priority patent/AU6505796A/en
Priority to EP96924664A priority patent/EP0840796A2/en
Priority to CA002227871A priority patent/CA2227871A1/en
Publication of WO1997005267A2 publication Critical patent/WO1997005267A2/en
Publication of WO1997005267A3 publication Critical patent/WO1997005267A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A composition for delivery of a polynucleotide to mucosal, neural, or other cells, comprising a GN1-binding protein and a polynucleotide in association with the binding protein; and a method for modulating immunity comprising administering the composition to an animal and expressing the polynucleotide whereby the animal generates an immune response to the product of the polynucleotide; and a method for gene therapy comprising administering to an animal a GM1-binding protein and a functional polynucleotide and expressing the polynucleotide in the animal whereby the function of the polynucleotide confers on the animal a therapeutic effect.
PCT/US1996/012041 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides WO1997005267A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP9507664A JPH11510164A (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides
AU65057/96A AU6505796A (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides
EP96924664A EP0840796A2 (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides
CA002227871A CA2227871A1 (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US152795P 1995-07-26 1995-07-26
US60/001,527 1995-07-26

Publications (2)

Publication Number Publication Date
WO1997005267A2 WO1997005267A2 (en) 1997-02-13
WO1997005267A3 true WO1997005267A3 (en) 1997-04-24

Family

ID=21696500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/012041 WO1997005267A2 (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides

Country Status (5)

Country Link
EP (1) EP0840796A2 (en)
JP (1) JPH11510164A (en)
AU (1) AU6505796A (en)
CA (1) CA2227871A1 (en)
WO (1) WO1997005267A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001527536A (en) * 1997-03-12 2001-12-25 ハイブライドン，インク． Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides
GB9713122D0 (en) * 1997-06-20 1997-08-27 Chiron Spa Novel method of DNA transfer into cells
ATE378066T1 (en) * 1998-09-30 2007-11-15 Wyeth Corp MUTATED CHOLERA HOLOTOXIN AS A REMEDY
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
KR20080078717A (en) 2001-06-07 2008-08-27 와이어쓰 홀딩스 코포레이션 Mutant form of cholera holotoxin as an adjuvant
BR0210225A (en) 2001-06-07 2004-09-08 Wyeth Corp Mutant immunogenic cholera holotoxin, immunogenic composition, method for enhancing a vertebrate host's immune response to an antigen, isolated and purified DNA sequence, nucleic acid molecule, host cell, method for producing a mutant immunogenic cholera holotoxin, and, use of a mutant cholera holotoxin
JP2005526769A (en) * 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Central airway administration for systemic delivery of therapeutic agents
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3094352B1 (en) 2014-01-16 2020-09-23 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI797430B (en) 2014-03-27 2023-04-01 中央研究院 Reactive labelling compounds and uses thereof
IL249188B2 (en) 2014-05-27 2024-03-01 Academia Sinica Anti-HER2 glycoantibodies and their uses
TWI670078B (en) 2014-05-27 2019-09-01 中央研究院 Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP6894239B2 (en) 2014-05-27 2021-06-30 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Compositions and methods for universal glycoforms for enhanced antibody efficacy
AU2015267044A1 (en) 2014-05-28 2016-12-15 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
CN107001404B (en) 2014-09-08 2021-06-29 中央研究院 Activation of human iNKT cells using glycolipids
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
EP3426693A4 (en) 2016-03-08 2019-11-13 Academia Sinica METHODS OF MODULAR SYNTHESIS OF N-GLYCANES AND N-GLYCAN CHIPS
TWI764917B (en) 2016-08-22 2022-05-21 醣基生醫股份有限公司 Antibodies, binding fragments, and methods of use

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006635A1 (en) * 1985-05-15 1986-11-20 Biotechnology Australia Pty. Ltd. Oral vaccines
JPS63258493A (en) * 1987-04-15 1988-10-25 Mitsui Toatsu Chem Inc Anti-ganglioside GM↓1 monoclonal antibody, cells producing it, and reagents comprising the same
EP0372928A2 (en) * 1988-12-07 1990-06-13 University Of Leicester Heat-labile toxin B subunit fusion proteins
EP0418626A2 (en) * 1989-09-08 1991-03-27 Takeda Chemical Industries, Ltd. Fused proteins and production thereof
WO1991007979A1 (en) * 1989-11-29 1991-06-13 Center For Innovative Technology Chimeric proteins
WO1993019183A1 (en) * 1992-03-23 1993-09-30 University Of Massachusetts Medical Center Immunization by inoculatioon of dna transcription unit
WO1994009823A1 (en) * 1992-11-03 1994-05-11 Oravax, Inc. Urease-based vaccine against helicobacter infection
WO1994023752A1 (en) * 1993-04-16 1994-10-27 University Of Portsmouth Enterprise Limited Drug delivery system
WO1995010301A1 (en) * 1993-10-08 1995-04-20 Duotol Ab Immunological tolerance-inducing agent
US5433946A (en) * 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006635A1 (en) * 1985-05-15 1986-11-20 Biotechnology Australia Pty. Ltd. Oral vaccines
JPS63258493A (en) * 1987-04-15 1988-10-25 Mitsui Toatsu Chem Inc Anti-ganglioside GM↓1 monoclonal antibody, cells producing it, and reagents comprising the same
EP0372928A2 (en) * 1988-12-07 1990-06-13 University Of Leicester Heat-labile toxin B subunit fusion proteins
EP0418626A2 (en) * 1989-09-08 1991-03-27 Takeda Chemical Industries, Ltd. Fused proteins and production thereof
WO1991007979A1 (en) * 1989-11-29 1991-06-13 Center For Innovative Technology Chimeric proteins
US5433946A (en) * 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
WO1993019183A1 (en) * 1992-03-23 1993-09-30 University Of Massachusetts Medical Center Immunization by inoculatioon of dna transcription unit
WO1994009823A1 (en) * 1992-11-03 1994-05-11 Oravax, Inc. Urease-based vaccine against helicobacter infection
WO1994023752A1 (en) * 1993-04-16 1994-10-27 University Of Portsmouth Enterprise Limited Drug delivery system
WO1995010301A1 (en) * 1993-10-08 1995-04-20 Duotol Ab Immunological tolerance-inducing agent

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE XP002027270 *
LEHNER ET AL.: "Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein", SCIENCE, vol. 258, no. 5036, 1992, pages 1365 - 1369, XP000645284 *
LYCKE ETAL.: "The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity", EUR. J. IMMUNOL., vol. 22, no. 9, September 1992 (1992-09-01), pages 2277 - 2281, XP002058448, DOI: doi:10.1002/eji.1830220915 *
NASHAR ET AL.: "Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes", VACCINE, vol. 11, no. 2, 1993, pages 235 - 240, XP000645274 *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 063 (C - 568) 13 February 1989 (1989-02-13) *
PILLAI ET AL.: "Translational fusion of heat labile enterotoxin chain B and beta-subunit of human chorionic gonadotropin: periplasmic expression in Escherichiacoil and its immunogenicity", FEBS LETT., vol. 387, no. 1, 27 May 1996 (1996-05-27), pages 23 - 26, XP000645267 *
ROHRBAUGH ET AL.: "Gene transfer fior therapy and prophylaxis of HIV-1 infection", ANN. NEW YORK ACAD. SCI., vol. 685, 1993, pages 697 - 712, XP000645528 *
VAN DER HEIJDEN ET AL.: "Manipulation of intestinal immune response against ovalbumin by cholera toxin and its B subunit in mice", IMMUNOLOGY, vol. 72, no. 1, 1991, pages 89 - 93, XP000618947 *

Also Published As

Publication number Publication date
CA2227871A1 (en) 1997-02-13
AU6505796A (en) 1997-02-26
EP0840796A2 (en) 1998-05-13
WO1997005267A2 (en) 1997-02-13
JPH11510164A (en) 1999-09-07

Similar Documents

Publication Publication Date Title
WO1997005267A3 (en) Mucosal delivery of polynucleotides
EG18726A (en) 1-Nitro-2,2 diaminoethylene derivatives and their use in pest control.
AU2993297A (en) Treatment of sickle cell disease, treatment of immune system diseases and other diseases normally associated with sickle cell anemia
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
IL118201A0 (en) Erythropoietin free of animal proteins processes for production and use thereof
HUP9801216A3 (en) Dna molecules, preparation thereof and use thereof in gene therapy
HUT69284A (en) Novel benzoyl amino acid derivs., pharmaceutical compns. conth. them and process to prepare them
EP0853121A3 (en) Human DNase
ZA947122B (en) Drug binding protein.
WO2002084298A3 (en) Medicaments which are modulators of hm74 and/or hm74a activity
AU5229793A (en) Novel extracts of cucurbita sp., process for their preparation and use in medicaments and in cosmetics
IL113373A0 (en) A plant gene for resistance to vascular diseases and protein encoded thereby
AU3477295A (en) Modified proteins
WO1998007829A2 (en) Use of flexible plastic tanks in gene theraphy
EP0853486A3 (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
EP0181634A3 (en) Synthetic gene for human lysozyme
EP0853486A4 (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
AU8239298A (en) Nucleotide-comprising composition
WO1997012963A3 (en) A paf-acetylhydrolase and use in therapy
IE860212L (en) Polypeptide factors from colostrum
EP0811687A3 (en) Polypeptides having l-asparaginase activity
EP0273778A3 (en) Synergistic behavior of csf-1 and g-csf
EP0572139A3 (en) Enzymatic protein process and product.
NZ332688A (en) Stimulation of host defence mechanisms against tumors using interferon
FI883255L (en) HUMAN PAPILLOMAVIRUS, TYPE 41 ITS DNA AND THE PROTEIN ENCODED BY THE DNA.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2227871

Country of ref document: CA

Ref country code: JP

Ref document number: 1997 507664

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2227871

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996924664

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996924664

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996924664

Country of ref document: EP